Clinical Trial Update: Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma [NA]

View source ↗

Summary

A clinical trial evaluating denileukin diftitox in combination with chemotherapy for newly diagnosed T-cell non-Hodgkin lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• Ontak (denileukin diftitox) (denileukin diftitox)

Snippet

Sponsor: University of Miami | Conditions: Lymphoma | NA | Status: WITHDRAWN